Cannabis
Empower Clinics Announces Record Preliminary Unaudited Q3 2019 Revenue with 138% year over year increase and Details for Release of Financial Statements
EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, a multi-state operator of medical health & wellness clinics, a CBD product producer and operator of an extraction facility in Oregon, is pleased to announce preliminary unaudited year over year revenue growth of 138% for the three months ended September 30, 2019. The company also decreased total direct clinic expenses by approximately 40%, while adding six new clinics as a result of the Sun Valley clinics acquisition.
The Company also has patient visits in corporate clinics increase by triple digits, with October 2019 patients seen increasing by 336% to 1,847 versus October 2018 with 550 patients seen.
“The Company is starting to feel the positive impact that the Sun Valley clinics acquisition has provided with their strong operational performance in Arizona, in conjunction with continued cost cutting measures with operations in Oregon and Washington State,” said Steven McAuley, CEO of Empower. “We have also been able to integrate key back office, admin, payroll & human resource functions from the Pacific Northwest into the operational controls of Sun Valley, bringing improved productivity to the organization.”
As part of the Company’s continued expansion of our health & wellness clinic model, we have already set up retail CBD product sales in-clinic, and now we have launched expanded physician based services starting with key Arizona clinics.
New Modalities and Services
- Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions
- CBD-Cannabis-Supplement Consumption & Coaching Consultation
- Introduction to Alternative Health and Cannabinoid Therapies by a Physician
- Comprehensive Naturopathic Patient Analysis & Consultation
- Dietary Antigen Testing, Physician Consultation/Action Plan, & Concierge Blood Draw
- Neurotransmitter (urine) Profile & Physician Consultation/Action Plan
- Spectracell Micronutrient Test & Physician Consultation/Action Plan
Empower plans to release its third quarter results ending September 30th, 2019 on November 14, 2019 at 9:00AM Eastern time.
Financial Measures
This news release makes reference to certain non-IFRS measures, including certain industry metrics. These metrics and measures are not recognized measures under IFRS do not have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review of our financial information reported under IFRS. These non-IFRS measures, including the industry measures, are used to provide investors with supplementary measures of our operating performance that may not otherwise be apparent when relying solely on IFRS metrics.
SOURCE Empower Clinics Inc.
-
Cannabis1 week ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis1 week ago
IM Cannabis Reports First Quarter Financial Results
-
Innocan1 week ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis5 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
Cannabis5 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis4 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
-
Cannabis3 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
Cannabis2 days ago
Rubicon Organics Reports Q1 2024 Financial Results